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 For several years, the standard of management in case of melanoma metastases in regional lymph nodes was to remove 
an adequate node group. In 2016 and 2017, the results of two large, well-designed clinical trials with randomization and 
a control group were published, which changed the current management. The authors of DeCOG-STL study came to 
the conclusion that withdrawal from completion lymph node dissection in the case of a small melanoma metastasis in 
a sentinel lymph node (metastasis diameter ≤1 mm) is not associated with a worsening of the 3-years’ survival chance 
(both in terms of overall survival and survival time to the occurrence of distant metastases). The results of MSTL-II study 
were similar. Based on the results of both studies presented above, in 2018 the American Society of Clinical Oncology 
(ASCO) and the Society of Surgical Oncology (SSO) presented joint recommendations concerning, among others, current 
indications for completion lymph node dissection in SNB positive melanoma patients.
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Introduction
For several years, the standard of management in case of me-
lanoma metastases in regional lymph nodes (both clinically/
cytologically confirmed and by means of sentinel lymph node 
biopsy) was to remove an adequate node group. For example, 
the recommendations of Sociedad Española de Oncología 
Médica (SEOM) formulate this principle as follows: “lymph 
nodes must be completely removed when there is a metastasis 
in a sentinel lymph node or when there is a clinical finding 
of metastasis (i.e. degree IIIB or IIIC) [1].” SEOM described the 
strength of this recommendation as A (strong) and the evi-
dence base as 2A. Therefore, the scientific premises for such 
a procedure at the time of publication of the recommenda-
tion did not raise any doubts. This strategy was unanimously 
confirmed by the recommendations of other organizations, 
including the national recommendations of the Polish Society 
of Clinical Oncology [2].
In 2016 and 2017, the results of two large, well-designed 
clinical trials with randomization and a control group were 
published, which changed the current management and re-
sulted in the content modification of clinical recommenda-
tions, both global and national [3, 4]. The above mentioned 
studies were based on data available in the medical literature 
suggesting that completion lymph node dissection (CLND) – 
i.e. lymphadenectomy following the confirmation of metastasis 
in a sentinel lymph node – in a certain group of patients does 
not bring any additional benefit in terms of total survival time 
compared to therapeutic lymph node dissection (TLND) [5]. 
Moreover, it has been observed in both small and large groups 
of patients that clinical practice differs significantly from the 
academic canon in the case of e.g. metastases in the sentinel 
lymph node [6, 7]. For example, in a group of approximately 
125 000 melanoma patients undergoing a sentinel lymph node 
biopsy in the USA (2002–2012), metastasis in this node was 
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found in approximately 25 000 patients. However, completion 
lymph node dissection was performed only in about 13 000 
patients, which accounted for slightly more than half (56%) 
of all patients in whom the procedure should be performed 
according to the commonly accepted indications [7].
DeCOG-SLT study
The first study, which changed clinical practice, was designed 
in Germany and conducted at 41 skin cancer treatment centers 
there, between 2006 and 2014 [3]. The study included 483 patients 
with melanoma of the trunk or a limb with a metastasis in the 
sentinel lymph node (selection criteria are presented in table I). 
The study participants were randomly assigned to two com-
pared groups: 242 patients were qualified for completion lymph 
node dissection and 241 for follow-up with strict ultrasound 
control of the relevant nodal group. It should be emphasized 
that about 2/3 of the participants had a small metastasis in the 
sentinel lymph node – a diameter ≤1 mm. The median of the 
follow-up period was 35 months. The percentage of patients 
surviving 3 years without distant metastases was 77.0% (90% 
confidence interval – CI: 71.9–82.1) in the group of patients under 
follow-up and 74.9% (95% CI: 69.5–80.3) in the group of patients 
undergoing completion lymph node dissection. The total percen-
tage of patients surviving 3 years was 81.7% (90% CI: 76.8–86.6) 
in the observation group and 81.2% (95% CI: 76.1–86.3) in the 
completion lymph node dissection group. The small percentage 
differences between the two endpoints were not significant. The 
authors of the study – noting its weakness resulting from insuffi-
cient number of participants in relation to the intended number 
(underpowered) – came to the conclusion that withdrawal from 
completion lymph node dissection in the case of a small lesions 
of melanoma metastasis in a sentinel lymph node (metastasis 
diameter ≤1 mm) is not associated with a worsening of the 3-years’ 
survival chance (both in terms of overall survival and survival time 
to the occurrence of distant metastases). In a non-inferiority study, 
this conclusion seems to be justified [3]. 
MSLT-II study
The second of studies mentioned above, MSLT-II, was conduc-
ted mainly in the USA between 2004 and 2014 with a similar 
patient group as in the German study. A significant difference 
between the two studies was the fact that MSLT-II also included 
patients with scalp and neck melanoma [4]. The study was 
multi-center in nature, it was conducted with randomization 
and a control group. The objective of the study was to com-
pare the results of completion lymph node dissection after 
excision of sentinel node containing melanoma metastasis 
with exclusive follow-up (without completion lymph node 
dissection). It is worth noting that the median size of the 
metastatic lesion in the sentinel lymph node was about 0.65 
mm in study participants and in over 2/3 of patients the size 
of the metastatic lesion did not exceed 1 mm. After 3 years 
there were no significant differences between the compared 
groups in terms of survival time, including melanoma specific 
survival (86.13% vs. 86.12%; p = 0.43). The authors of this study 
observed a borderline significance (p = 0.05) in terms of the 
percentage of patients surviving 3 years without symptoms 
of the disease in favor of the group undergoing completion 
lymph node dissection (68% vs. 63%), which resulted from 
better local control after that time in the group of patients 
undergoing lymphadenectomy (92% vs. 77%; p < 0.001). At 
the same time, the authors demonstrated several times higher 
Table I. Selection criteria for the DeCOG-SLT study
Inclusion criteria Exclusion criteria
Primary skin melanoma of the trunk or limb Melanoma located within the head and neck
Patient age: 18–75 years Satellite tumors/in transit
Melanoma thickness according to Breslow ≥1 mm M1
SLB + (micrometastasis and isolated neoplastic cells) Macrometastasis 
SLB + – positive result of sentinel node biopsy; M1 – current distant metastases (M parameter according to TNM)
Table II. Results of DeCOG-SLT and MSLT-II studies, in which the CLND was compared with exclusive follow-up after a sentinel node biopsy and metastasis 
confirmation
Study Number of patients Median time of observation Results (follow-up vs. CLND)
Leiter et al.
DeCOG-SLT [3]
483 34 months OS HR 1.02, p = 0.95 
10-year OS 62.6% vs. 61.9% 
RFS HR 0.959 
DMFS HR 1.19 
10-year DMFS 55.8% vs. 55.5%
Faries et al.
MSLT-II [4]
1755 43 months MSS HR 1.08, p = 0.42 
DMFS HR 1.1 
follow up 63% vs. DFS CLND 68% 
CLND – completion lymph node dissection; DFS – disease-free survival; DMFS – distance metastases-free survival; HR – hazard ratio; OS – overall survival; RFS – relapse-free 
survival; MSS – microsatellite stability
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risk of lymphedema in the group undergoing lymphadenec-
tomy compared to the group undergoing only sentinel node 
biopsy and follow-up (24.1% vs. 6.3%; p < 0.001). The authors 
of the MSLT-II study concluded that completion lymph node 
dissection increases the percentage of local control, but does 
not improve survival by taking into account the cause of de-
ath. However, it contributes to a  significant increase in the 
incidence of a serious complication, which the limb’s lympho-
edema. Therefore, they recommended limiting the indications 
to completion lymph node dissection in patients with clinical 
characteristics that corresponded to the characteristics of the 
study participants (mainly low metastatic mass in the sentinel 
lymph node) [4].
Table II presents a summary of the results of both studies 
– DeCOG-SLT and MSLT-II. Both cited studies confirmed the 
basic prognostic role of sentinel node biopsy. 
Summary
Based on the results of both studies presented above, in 2018 
the American Society of Clinical Oncology (ASCO) and the 
Society of Surgical Oncology (SSO) presented joint recom-
mendations concerning, among others, current indications for 
completion lymph node dissection [8]. The course of action 
suggested in these recommendations is presented in figure 1. 
However, clinical follow-up as a management option may 
be used only in patients with a small metastatic lesion in a 
sentinel lymph node (metastasis diameter does not exceed 
1 mm), not burdened with other prognostic factors that may 
increase the risk of melanoma metastases in non-sentinel 
lymph nodes (metastatic lesion diameter in a sentinel lymph 
node, number of occupied sentinel lymph nodes, thickness/
presence of ulceration in the primary lesion) [9]. 
Also in the Polish recommendations on melanoma publi-
shed in 2017 and 2019, the follow-up with a strict ultrasound 
monitoring of the lymphatic flow area after a sentinel lymph 
node biopsy, which confirmed the presence of a small me-
lanoma metastasis, was presented as an acceptable course 
of action [10, 11]. The authors of joint ASCO and SSO recom-
mendations emphasize that in the case of follow-up, strict 
ultrasound supervision over regional lymph nodes is necessary 
every 4–6 months (strength of recommendation according to 
ASCO – strong) [8].
In clinical practice, the role of completion lymph node 
dissection is gradually reduced and individualized, however, 
each patient who has not undergone this procedure must 
be subject to strict supervision, including ultrasound evalu-
ation of regional lymphatic flow every 3-4 months. Moreover, 
patients should be consulted with regard to the possibility of 
implementing systemic complementary treatment [11]. This 
issue is described in another article in this issue of Nowotwory.
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Figure 1. Management in case of positive results of sentinel node 
biopsy in melanoma patients (based on ASCO and SSO 2018 common 
recommendations [8])
